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Abstract
The mucin MUC4 and its membrane partner the ErbB2 oncogenic receptor are potential interacting partners in human
pancreatic tumour development. However, the way they function is still largely unknown. In this work, we aimed to identify
the cellular mechanisms and the intracellular signalling pathways under the control of both ErbB2 and MUC4 in a human
pancreatic adenocarcinomatous cell line. Using co-immunoprecipitation and GST pull-down, we show that MUC4 and ErbB2
interact in the human pancreatic adenocarcinomatous cell line CAPAN-2 via the EGF domains of MUC4. Stable cell clones
were generated in which either MUC4 or ErbB2 were knocked down (KD) by a shRNA approach. Biological properties of
these cells were then studied in vitro and in vivo. Our results show that ErbB2-KD cells are more apoptotic and less
proliferative (decreased cyclin D1 and increased p27kip1 expression) while migration and invasive properties were not
altered. MUC4-KD clones were less proliferative with decreased cyclin D1 expression, G1 cell cycle arrest and altered ErbB2/
ErbB3 expression. Their migration properties were reduced whereas invasive properties were increased. Importantly,
inhibition of ErbB2 and MUC4 expression did not impair the same signalling pathways (inhibition of MUC4 expression
affected the JNK pathway whereas that of ErbB2 altered the MAPK pathway). Finally, ErbB2-KD and MUC4-KD cells showed
impaired tumour growth in vivo. Our results show that ErbB2 and MUC4, which interact physically, activate different
intracellular signalling pathways to regulate biological properties of CAPAN-2 pancreatic cancer cells.
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Introduction
Pancreatic Ductal Adenocarcinoma (PDAC) is the 4th leading
cause of death by cancer in the world. The survival curve is
extremely short (6 months) and the survival rate at 5 years is very
low (3%). This dramatic outcome is related to a lack of therapeutic
tools and early diagnostic markers which makes pancreatic cancer
the most deadly cancer. At the time of diagnosis, more than 80%
of PDAC are already metastatic or locally advanced and only
about 10 to 15% of patients are considered eligible for surgical
resection. Pancreatic carcinogenesis follows a metaplasia/dyspla-
sia/cancer progression with PDAC developing from ductal lesion
precursors called Pancreatic Intraepithelial Neoplasia (PanIN-
1A/-1B/-2/-3) in which histologic, cytologic and genetic alter-
ations accumulate [1,2]. Identification of new molecular targets,
especially those with altered expression in early PanIN, and
deciphering the molecular mechanisms underlying the disease, will
undoubtedly allow the development of new therapeutic approach-
es to stop/slow down tumour progression.
In this context, the membrane-bound mucin MUC4, which is
expressed as early as in PanIN-1A whereas it is not expressed in
the healthy pancreas, and its membrane partner the oncogenic
receptor ErbB2 which is frequently overexpressed in pancreatic
cancer as well as in PanINs, represent promising therapeutic
targets [3,4,5,6].
The MUC4 gene encodes a large apomucin (930 kDa)
composed of two subunits MUC4a and MUC4b [7,8,9,10].
MUC4a is the extracellular subunit featuring a typical hypergly-
cosylated region. MUC4b is the trans-membrane subunit
containing three EGF-like domains (EGF3, EGF1 and EGF2
located from C-terminus to N-terminus) that are conserved in
humans and rodents [4,11]. Experimental evidence with rat
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domains play a role in receptor-ligand interactions and are a
regulator in signalling related to growth, motility or differentiation
of the cell [4,12]. From these data, Carraway and collaborators
have proposed Muc4 as a modulator of the proliferation/
differentiation balance [13] but at this time, such proposed
mechanism has not been validated for human MUC4.
The oncogene neu encodes ErbB2/HER2 type I transmem-
brane growth factor receptor that belongs to the epidermal growth
factor receptor (EGFR/ErbB1) family comprising ErbB3 and
ErbB4. The ErbB2 protein consists in an extracellular domain, a
transmembrane domain and an intracellular tyrosine kinase
domain. ErbB2 has no known ligand and is described as a co-
receptor which hetero-dimerizes with the other ErbB receptors
[14]. ErbB2 is commonly overexpressed in cancers, including
PDAC, where ErbB2 is frequently amplified.
Studies in human cells remain scarce and suggest so far a
possible role for MUC4 in the biological properties of pancreatic
cancer cells [15,16]. Regarding ErbB2, only one recent study in
another pancreatic cancer cell model has shown that ErbB2 may
be involved in the properties of pancreatic cancer cells [17].
Previous works in colon and pulmonary cells showed that MUC4
and ErbB2 may act as a functional complex and transduce signals
intracellularly [18,19]. However, it remains unclear whether
MUC4 and ErbB2 activate the same signalling pathway(s).
In the present work, we undertook to identify the intracellular
signalling pathways under the control of either ErbB2 or MUC4 in
the same cellular model of pancreatic cancer to test this
hypothesis. We show that human MUC4 and ErbB2 do physically
interact in pancreatic cancer cells and that inhibition of expression
of each membrane partners does not impair the same signalling
pathways (inhibition of MUC4 expression affects the JNK
pathway whereas that of ErbB2 alters the MAPK pathway).
Different effects on the biological properties of pancreatic cancer
cells were observed, suggesting independent activities of these two
proteins with a role in pancreatic tumour growth for ErbB2, while
MUC4 appears to be involved in both tumour growth and
dissemination.
Materials and Methods
Establishment of ErbB2 and MUC4 KD cell lines
The CAPAN-2 pancreatic cancer cell line (ATCC, HTB-80)
was cultured as previously described [20]. ErbB2-KD cells were
obtained following stable transfection of CAPAN-2 cells with
pGeneClip
TM puromycin vector encoding ErbB2 ShRNA (SA
Biosciences
TM). Stable transfection of 1 mg of ScaI digested
plasmid was performed with EffecteneH (Qiagen, Courtaboeuf,
France) following manufacturer’s protocol. The empty vector was
used to raise control clones called Non Targeting (NT). Selection
was performed using puromycine (0.1 mg/ml, InvivoGen, Li-
moges, France) and clones were isolated by limited serial dilution.
MUC4-Knocked Down (KD) cells were obtained by retroviral
infection of CAPAN-2 cells with pRetroSuper plasmid (SA
Biosciences
TM) containing a sequence targeting MUC4 (59-
AAGTGGAACGAATCGATTCTGTTCAAGAGACAGAATC-
GATTCGTTCCACTT-39). The empty vector was used to raise
control clones called Mock. Selection was performed using G418/
geneticine (300 mg/ml, Invitrogen, Cergy Pontoise, France) and
clones were isolated by serial limit dilution.
Western blotting
Cytosolic, nuclear and total cellular extracts were prepared as
described in Van Seuningen et al. [21] and Jonckheere et al. [22],
respectively and kept at 280uC until use. Protein content (2 mlo f
nuclear extracts) was measured in 96-well plates using the
bicinchoninic acid method as described in the manufacturer’s
instruction manual (Pierce). Western blotting was carried out on
nitrocellulose membrane (0.2 mm, Schleicher and Schuell) as
previously described [23]. Membranes were probed with antibod-
ies against ErbB-2 (clone Ab-1, dilution 1/500), p27kip1 (dilution
1/500) from Lab Vision Neomarker, USA; phospho-p42/
44MAPK (Thr202/Tyr204) (clone 20G11, dilution 1/500), p42/
44MAPK (clone I37F5, dilution 1/500), phospho-SAPK/JNK
(Thr183/Tyr185) (#9251, dilution 1/500), SAPK/JNK (clone
56G8, 1/500), phospho-p38MAPK (Thr180/Tyr182) (clone
D3F9, 1/1000), p38MAPK (#9212, dilution 1/1000), FAK
(#3285, dilution 1/1000), phospho-Akt (Ser473) (clone D9E, 1/
1000), Akt (clone C67E7, dilution 1/1000), cyclin D1 (clone
DCS6, dilution 1/500), EGFR (#2232, dilution 1/500), all from
Cell Signaling Technology, USA; ErbB-3 (clone C-17, 1/500),
ErbB-4 (clone C-18, dilution 1/500), MMP2 (clone H-76, dilution
1/500), MMP9 (clone 6-6B, dilution 1/500), Bcl-xL (clone H-5,
dilution 1/500), Bax (clone N-20, dilution 1/500), MUC4 (8G7,
dilution 1/500) all from Santa Cruz Biotechnology, USA; MUC1
(M8, generous gift from Dr D. Swallow, London), or b-actin
(A5441, dilution 1/5000) from Sigma, France. Antibodies were
diluted in Tris-Buffered Saline containing 5% (w/v) non-fat dry
milk and Tween-20 (TBS-T), except for MUC4 and b-actin and
incubated overnight at 4uC before processing with immunostain-
ing. Peroxidase-conjugated secondary antibodies (Sigma) were
used and immunoreactive bands were visualised using the West
Pico chemoluminescent substrate (Perbio, Brebie `res, France).
Chemo-luminescence was visualised using LAS4000 apparatus
(Fujifilm) and results were integrated using Gel analyst softwareH
(Claravision). The data presented are representative of three
independent experiments.
Co-immunoprecipitation of the MUC4-ErbB2 complex
150 mg of CAPAN-2 cellular extract were incubated overnight
with 1.5 mg of anti-ErbB2 antibody (Rabbit polyclonal, Ab-1,
Thermo Scientific). Protein A was covalently attached to cross-
linked 4% agarose beads (Sigma, France), equilibrated with 16
binding buffer (200 mM Tris-HCl pH 7.5 containing 1 M NaCl,
20 mM EDTA, and 2% NP40 (v/v)) and added to the lysate-
antibody mix and incubated on a rotating platform for 2 h at 4uC.
Beads were then washed three times with 16 binding buffer.
Rabbit IgGs (Millipore) were used as a negative control. Washed
beads were then mixed with 26 SDS gel loading buffer before
electrophoresis on a 2% (w/v) agarose gel and immunoblotting as
described before [23].
Construction of the GST-MUC4EGF3+1+2 fusion protein
The cDNA encoding the MUC4EGF3+1+2 sequence was
amplified by PCR using a FLAG epitope-tagged version of the
MUC4b subunit [16] called MUC4F2-CF2 as the template and
F_EGF3 (59-CGCGGATCCGCCTGTGAGGAGCCG-39) and
R_EGF1 (59-TCCCCCGGG TCAGAAGCAGCGGCTGTC-39)
as primers. The PCR product encoding MUC4EGF3+1+2 was
digested by BamHI and SmaI and inserted into pGEX-4T1 (GE
Lifesciences). The pGEX-4T1-GST-MUC4EGF3+1+2 construct was
then transfected in B834pLysS E. coli (Novagen) using electropo-
ration and E. coli was grown in Luria Bertani medium (Invitrogen)
to an OD600 of 0.8. GST-MUC4EGF3+1+2 fusion protein
expression was then induced by adding 1 mM of isopropylthio-
galactopyranosyl (Ambion) at 15uC overnight. The cells were
harvested by centrifugation at 38006 ga t4 uC, resuspended in
60 ml lysis buffer (16PBS, 1 mM DTT, 1 mM EDTA, 1% (v/v)
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After centrifugation (20 0006 g, 90 min, 4uC), the supernatant
was recovered, and GST-MUC4EGF3+1+2 was separated from the
whole-cell lysate using glutathione agarose beads (Qiagen). After
washing beads with lysis buffer, GST-MUC4EGF3+1+2 fusion
protein was eluted by 40 mM of reduced glutathione in a
50 mM Tris-HCl pH 8.0 buffer containing 150 mM NaCl,
0.1% (v/v) Triton X/100 and 1 mM DTT. Protein purity was
determined by Coomassie blue staining after a 12% SDS-PAGE.
The purified protein was dialysed against 16binding buffer and
stored at 4uC until use.
GST pull-down
The GST-MUC4EGF3+1+2 was loaded on equilibrated glutathi-
one beads (Qiagen,) as described by the manufacturer. After
overnight binding at 4uC in the presence of the human
recombinant ErbB2 protein (5 mg, R&D systems, Lille, France),
the glutathione beads were washed 3 times with 16binding buffer.
The washed beads were then mixed with 26SDS loading buffer
and boiled at 100uC for 5 min. The supernatant was loaded on a
6% SDS-PAGE and blotted on a PVDF membrane. ErbB2
Western blotting was carried out as described above.
Proximity ligand assay
In situ proximity ligand assays were performed using Duolink II
Red Starter Kit (Olink, UPPSALA, Sweden) following the
manufacturer’s protocol. Briefly, 2.5610
5 cells were seeded in a
Chamber Slide permanox (Nunc, Brumath, France) and incubated
72 h to reach 70–80% confluence. Cells were fixed 20 min with
4% (v/v) paraformaldehyde at RT before a blocking step with the
blocking solution for 30 min at 37uC. Primary antibodies against
MUC4 (8G7) and ErbB2 (C-18) were diluted at 1/50 in 16PBS
pH 7.4 and incubated for 90 min at RT. PLA probe anti-rabbit
PLUS and anti-mouse MINUS were diluted at 1/5 in antibody
diluent, and incubated with cells 1 h at 37uC after two washing
steps. Ligation and amplification were then performed at 37uCi n
order to visualize the complex. Slides were mounted with Duolink
II Mounting Medium containing DAPI. Stainings were visualized
with a Zeiss LSM 710 confocal microscope (Zeiss, Jena, Germany),
images were captured and analysed with the Zeiss Efficient
Navigation software (Zeiss, Jena, Germany).
Confocal microscopy
Confocal microscopy was carried out as previously described
[24]. MUC4 (8G7, Santa Cruz) and ErbB2 (C-18, Santa Cruz)
antibodies were used at the 1/50 dilution in 16 D-
PBS+Mg
2++Ca
2+ (Invitrogen) containing 0.2% (w/v) saponin
and 2% (v/v) goat serum. AlexaFluorH 594 goat anti-mouse and
AlexaFluorH 488 goat anti-rabbit (Invitrogen) secondary antibod-
ies were respectively used to detect MUC4 and ErbB2 expression.
Migration and Invasion assays
Cell migration and invasion properties of the different clones
were assessed using respectively 24 well control Boyden chambers
(8 mm pores) and chambers coated with MatrigelH matrix (BD
Biosciences, le Pont de Claix, France) following manufacturer’s
protocol. Briefly, 10% (v/v) foetal bovine serum was used as
chemoattractant in the lower chamber. 5610
4 cells were plated in
the top chamber and incubated for 48 h. After staining with
DiffQuick (Mediane Diagnostics, Plaisir, France), cells on the
lower surface were counted using light microscopy at 6100
magnification. Eight random vision fields were counted and the
experiment was repeated four times.
Flow Cytometry
Cells were cultured during 24 h before being harvested by
trypsinization, and then resuspended in 16 PBS. The cells were
fixed by addition of 1 ml of 70% (v/v) ethanol and incubation on
ice for 30 min. Cells were then washed with 16PBS, treated for
5 min with RNase A (100 mg.ml
21) and finally stained with
propidium iodide (50 mg.ml
21, Sigma) for 30 min. Cell analysis
was carried out on a Beckman Coulter EPICS XL3-MCL
(Villepinte, France) using the Wincycle software (Phoenix Flow
Systems, San Diego, CA, USA).
Subcutaneous xenografts
Subcutaneous (SC) xenografts (6610
6 cells in 150 ml of RPMI
1640) of CAPAN-2 clones were injected with 150 ml of MatrigelH (ref
354262, BD Biosciences, le Pont de Claix, France) into severe-
combined immunodeficient (SCID) mice that were bred and
maintained under pathogen-free conditions (6 mice/cell type).
Tumour development was followed periodically. The tumour
volume (mm
3) was determined by calculating V=W
26L/2 in which
W corresponds to the width (in mm) and L to the tumour length (in
mm). Mice were killed 55 days after inoculation. All procedures were
in accordance with the guideline and approved by the animal care
committee (Comite ´E t h i q u eE x p e ´rimentation Animale Nord Pas-de-
Calais, Permit/Protocol number: AF042008). For each SC tumour,
tissue was fixed informalin before paraffin inclusion. Mice presenting
features of pain (weight loss, cachexia, piloerection) or bearing
tumour reaching 1 cm
3 were sacrificed.
Immunohistochemistry
SC xenografted tissues were fixed in 10% (w/v) buffered
formaldehyde, embedded in paraffin, cut at 4 mm thickness and
applied on SuperFrostH slides (Menzel-Glaser, Braunschweig,
Germany). Slides were then stained with Hematoxylin-Eosin-
Saffron-Astra blue. Manual immunohistochemistry (IHC) was
carried out as described in Van der Sluis et al [25] and automatic
IHC with an automated immunostainer (ES, Ventana Medical
System, Strasbourg, France) as in Mariette et al [26]. The
antibodies were used as followed: 1:200 dilution of anti-ErbB2
(DAKO), 1:100 of anti-MUC4 8G7 (Santa Cruz Biotechnology)
and 1:50 of anti-MUC1 M8.
DNA Microarray analysis
Comparative transcriptome analyses were conducted on four
MUC4-KD and four ErbB2-KD cellular clones. They were
compared to a pool of four Mock and four NT cellular clones,
respectively. RNA quality was checked using the Agilent 2100
Bioanalyser (Agilent Technologies, Massy, France). cRNA samples
were synthesized using low input RNA fluorescent linear
amplification kit (Agilent). Hybridization of Cy3 and Cy5 labelled
cRNA was performed on the human 44 K pangenomic 60 mer
oligonucleotide microarray (Agilent) according to the manufac-
turer’s protocol. Microarrays were scanned using the Agilent
scanner G2505C and Feature Extraction software (v10.5). Data
were processed with the GeneSpring software (v10) for normal-
ization, filtering, and statistical analysis. The genes upregulated or
downregulated (fold change .5) with statistical significance
(P,0.05) were sorted using asymptotic P value computation. All
data are MIAME compliant. The raw data has been deposited in
Gene Expression Omnibus (GEO, accession number: GSE31322).
qRT-PCR
Total RNAs from pancreatic cancer cells were prepared using
the NucleoSpinH RNA II kit (Macherey Nagel) following
MUC4 & ErbB2 Activate Different Signaling Pathways
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described [27]. PCR was performed using SsoFast
TM Evagreen
Supermix kit following manufacturer protocol using the CFX96
real time PCR system (Biorad). Primer information is given in
table S1.
Statistical analysis
Statistical analyses were performed using Graphpad Prism 4.0
software (Graphpad softwares Inc., La Jolla, USA). Data are
presented as mean 6SEM. Differences in the mean of two samples
were analysed by the student’s t test or one way ANOVA test with
selected comparison using Tukey’s HSD post-hoc test with
differences less than 0.05 considered significant and were indicated
with an *. ** indicates p,0.01, *** indicates p,0.001. Differences
of contingency were analysed using Chi square test.
Results
MUC4 and ErbB2 physically interact in the CAPAN-2
pancreatic cancer cells
Immunoprecipitation of CAPAN-2 cellular extract with anti-
ErbB2 antibody was performed before immunoblotting with anti-
MUC4 antibody. MUC4 immunostaining indicates that MUC4
co-immunoprecipitated with ErbB2 in CAPAN-2 cells (Figure 1A,
lane 1). Specificity of the interaction was assessed using irrelevant
rabbit IgGs that showed no immunoprecipitated band (lane 2). In
order to show a direct physical interaction between MUC4 and
ErbB2, we first carried out a GST pull-down assay. For that, we
made a GST-MUC4EGF3+1+2 fusion protein which contains the
three EGF-like domains of MUC4. We then prepared two affinity
columns bearing either the GST-MUC4EGF3+1+2 fusion protein or
the GST alone on which recombinant human ErbB2 was loaded.
Following affinity chromatography, anti-ErbB2 immunoblot
showed an ErbB2 specific band for the glutathione beads column
bearing the GST-MUC4EGF3+1+2 fusion protein (Figure 1B, lane 1).
No bands were observed for the glutathione column bearing GST
alone (lane 2).
Interaction between MUC4 and ErbB2 was then confirmed
using another approach that is the in situ proximity ligation assays
(PLA). The results indicate that MUC4 and ErbB2 form an
endogenous complex in CAPAN-2 cells (red dots, arrows,
Figure 1C). Finally, confocal microscopy studies confirmed the
co-localisation of MUC4 and ErbB2 in CAPAN-2 cells
(Figure 1D). Altogether, these results indicate that MUC4 and
ErbB2 physically interact in CAPAN-2 pancreatic cancer cells via
MUC4EGF3+1+2 region that contains the three EGF-like domains.
We then undertook to identify the cellular mechanisms and the
intracellular signalling pathways under the control of both
partners.
Generation and characterization of stable ErbB2-KD and
MUC4-KD cellular clones
The five ErbB2-KD and seven MUC4-KD cellular clones
showed respectively almost complete or total inhibition of ErbB2
and MUC4 expression compared to control clones (Figure 1E).
Western blot analysis of another membrane-bound mucin that is
important in cancer, MUC1, indicated that inhibition of MUC4
dramatically impaired that of MUC1 whereas inhibition of ErbB2
had no effect (Figure S1). When we looked at the expression of the
three other members of the ErbB receptor family, inhibition of
MUC4 or ErbB2 expression led to a strong decrease of ErbB2 and
ErbB3 (MUC4-KD) and of ErbB3 (ErbB2-KD), respectively,
whereas no effect was detected for ErbB1 and ErbB4 (Figure S1).
Role of ErbB2 and MUC4 on cell proliferation and
apoptosis
MUC4-KD cells showed a decreased proliferation from 48 h
that was sustained at 72 h and became significant at 96 h (44%
less than Mock cells, p,0.05). ErbB2-KD cells were also less
proliferative with a significant decrease of 27% at 96 h (p,0.05)
(Figure 2A). A strong cell cycle arrest in the G1 phase
(54.5%60.13) was observed in MUC4-KD cells when compared
with Mock cells (37.4%67.2, *, p=0.016) (Figure 2B). Moreover,
the G2M phase was much shorter in MUC4-KD cells
(20.9%64.7) compared to Mock control cells (39.6%66.7, **,
p=0.0035) (overall *, p=0.0102). In ErbB2-KD cells, a trend
toward a cell cycle arrest in G1 also occurred that remained
statistically non significant (p=0.119) (Figure 2B). In order to
identify the mechanisms responsible for this alteration in
proliferation, expression of cell cycle markers was evaluated by
Western blotting (Figure 2C). Clearly, decreased proliferation in
MUC4-KD cells was associated with repression of cyclin D1. In
ErbB2-KD cells, decreased proliferation was associated with both
increased expression of p27
kip1 cell cycle inhibitor and decrease of
cyclin D1 (Figure 2D), suggesting a cellular arrest at the G1/S
proliferation checkpoint.
To assess whether MUC4 or ErbB2 inhibition could also affect
apoptosis, measurement of apoptotic cell population (subG1 cells)
by flow cytometry was carried out (Figure 2E). The results
indicated a significant increase of subG1 population (13.33%62.1)
in ErbB2-KD cells when compared to NT control clones
(6.2%60.4) (*, p=0.017). In MUC4-KD cells, no differences in
subG1 cell population were observed when compared to Mock
control clones (ns, p=0.19). Expression of apoptotic markers by
immunoblotting indicated that Bax and BclXL were not altered in
both MUC4-KD and ErbB2-KD cells whereas increase of cleaved
caspase-3 was observed in ErbB2-KD cells (Figure 2F).
Role of MUC4 and ErbB2 in cell migration/invasion/
adhesion
To assess the role of MUC4 and ErbB2 in cell migration/
invasion, experiments were carried out in Boyden chambers
without or with MatrigelH coating, respectively. The results
indicated that a significant lower number of migratory cells was
observed in MUC4-KD cells (37.861.5) compared to Mock cells
(60.163.3) (p#0.001) whereas no significant difference was found
in ErbB2-KD cells (53.568.8) compared to NT control clones
(56.266.3) (Figure 2G). When we measured invasiveness, MUC4-
KD cells appeared significantly more invasive (41.8%61.5, n=7)
than cells expressing MUC4 (mock) (19.5%61.5, n=5) (p=0.029)
(Figure 2H). ErbB2-KD clones, on the other hand, were slightly
less invasive (9.4%61.15) than cells expressing ErbB2 (NT,
14.14%62.1) but this decrease was not significant (p=0.09).
The ability of MUC4-KD and ErbB2-KD cells to adhere on
MatrigelH (made of two components of the pancreatic extracellular
matrix collagen IV and laminin) or collagen I was also assessed but
no significant differences were found for either cells (not shown).
Role of ErbB2 and MUC4 in intracellular signalling
The impact of ErbB2 or MUC4 on the major pathways of
intracellular signalling was studied by Western blotting for:
MAPKs (p42/44, p38 and JNK), Akt, and Focal Adhesion Kinase
(FAK) (Figure 3 and Figure S2). Phosphorylation of p42/p44
MAPK was totally abolished in ErbB2-KD cells compared to NT
control clones, indicating complete inhibition of this pathway
subsequent to ErbB2 silencing. In MUC4-KD cells compared to
mock clones, constitutive p42/p44 MAPK decreased whereas
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PLoS ONE | www.plosone.org 4 February 2012 | Volume 7 | Issue 2 | e32232Figure 1. MUC4 and ErbB2 form a complex – Characterisation of MUC4-KD and ErbB2-KD cells. (A) Co-immunoprecipitation of 150 mgo f
CAPAN-2 cellular extract with anti-ErbB2 antibody (lane 1) or rabbit IgGs (lane 2). CAPAN-2 cell extract alone (lane 3). (B) ErbB2 immunoblot of GST
pull-down of recombinant human ErbB2 protein with GST-MUC4EGF3+1+2 glutathione beads (lane 1) or GST glutathione beads (lane 2). Recombinant
ErbB2 alone (lane 3). (C) In situ proximity ligand assay on CAPAN-2 cells. MUC4 and ErbB2 complexes (red dots) are indicated by an arrow. Nuclei were
stained using DAPI. Control experiment was conducted in the absence of primary antibody. (D) Immunofluorescence detection of MUC4 (red) and
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MAPK pathway linked to MUC4 suppression.
When we looked at the JNK pathway, a total repression of JNK
phosphorylation was observed in MUC4-KD clones compared to
Mock controls suggesting that MUC4 expression dramatically
impacts JNK pathway activity. No effect on the JNK pathway was
observed in ErbB2-KD clones. p38 MAPK pathway did not
appear to be significantly altered following either ErbB2 or MUC4
silencing (Figure 3). Similarly, Akt and FAK pathways were not
significantly modified (Figure S2).
Altogether, these results show that loss of MUC4 and ErbB2
dramatically impairs JNK and p42/44 MAPK signalling path-
ways, respectively.
Effect of ErbB2 and MUC4 on tumour properties in vivo
To confirm in vitro data of MUC4 and ErbB2 effects on tumour
cell properties, SC xenograft studies were carried out. The results
indicate that the tumour volume was significantly lower in
xenografted mice with M4-2-1 or M4-2-10 clones at day 22
(Figure 4A) in which absence of MUC4 was confirmed by IHC
(Figure 4B). Reduction of ErbB2 expression previously shown in
vitro by Western blotting was also confirmed in vivo in MUC4-KD
tumours by IHC (Figure 4B). The relative tumour volume was
0.1460.05 for M4-2-1 and 0.2260.03 for M4-2-10 (80–90%
decrease) when compared to Mock control tumour volume
(160.3). The decrease was statistically significant for both clones
(**, p=0.0012) (Figure 4A).
A significant reduction of tumour size was also observed in
tumours derived from EV9 (0.5560.17) and EV18 (0.186012)
ErbB2-KD cells when compared to NT controls (160.1, **,
p=0.017). As expected, a dramatic reduction of ErbB2 expression
in ErbB2-KD tumours was observed by IHC (Figure 4B).
Interestingly, MUC4 expression was strongly repressed in
ErbB2-KD tumours (Figure 4B) confirming the strong decrease
in MUC4 level in ErbB2-KD cells observed by immunoblotting
(see Figure 1).
Altogether, these results indicate that both ErbB2 and MUC4
play a role in pancreatic tumour growth in vivo.
Effect of ErbB2 and MUC4 on gene expression
In order to identify new pathways regulated by ErbB2 and
MUC4, comparative transcriptome analyses were carried out by
using DNA microarrays on expressing and non-expressing cell
lines (table S2 & S3, GEO accession number: GSE31322). In
ErbB2-KD cells, 254 and 61 genes were differentially expressed
with equal to and/or more than five or two-fold difference,
respectively in ErbB2-KD vs. Mock cells (p,0.01). In MUC4-KD
cells, over 2282 and 326 genes were altered with a five or two-fold
difference, respectively in MUC4-KD vs. Mock cells (Figure S3).
Notably, more genes were found down-regulated (n=209) than
up-regulated (n=117) following MUC4 silencing (fc.5, p,0.01).
Interestingly, only 37 (f.c..2) and 8 (f.c..5) altered genes were
common following ErbB2 and MUC4 silencing (p,0.01). Among
those, were found genes encoding ATPase, Ca
2+ transporting, type
2C, member 2 (ATP2C2) (NM_014861), integrin-b7 (ITG-b7)
(NM_000889), keratin81 (NM_002281), keratin86 (NM_002284),
Serpina3 (NM_001085), collagen type VIII alpha1 (NM_001850)
(f.c..5) and STAT1 (IFN-c signalling pathway) (NM_139266)
(f.c..2). Regulated genes in ErbB2-KD cells were related to
control of transcription, signal transduction, cell adhesion or
induction of apoptosis (table S4). Regulated genes in MUC4-KD
cells were related to control of transcription, DNA-dependent
transcription, signal transduction, cell cycle, apoptosis or cell
adhesion (table S5). Altered gene expression was then confirmed
by carrying out qRT–PCR. Consistent with microarray data,
increased expression of TGF-b1 and decreased expression of
MUC4, and carbonic anhydrase 9 (CA-9) was found in MUC4-
KD cells (Figure 5A). In a similar manner, up-regulation of CA-9,
ITG-b6, ITG-b7 and TGF-b1 and down-regulation of ErbB2,
and the calcium binding protein S100P was found in ErbB2-KD
cells (Figure 5B).
Discussion
The mucin MUC4 is thought to form a complex at the
membrane with the oncogenic receptor ErbB2 based on
biochemical studies with rat homologue of MUC4 [4,13,28]. Both
MUC4 and ErbB2 are overexpressed in several epithelial cancers
(pancreas, breast, lung, oesophagus, colon, ovary) and both have
been shown to play roles in tumour development [12,15,28,29,30].
The potential of these two membrane proteins as therapeutic
targets to slow down/stop tumour development is obvious and has
drawn a lot of attention to develop tools targeting them. However,
the direct interaction between human MUC4 and ErbB2 has not
been proven at this time, moreover, studies on their role in
regulating the biological properties of cancer cells have always
been carried out separately in different cellular models [3,15,17].
Moreover, if they function as a complex, we must understand the
molecular mechanisms that both proteins control in cancer cells in
order to develop tools that will target the complex.
In this work, we have undertaken to study the biological
consequences of both MUC4 and ErbB2 suppression in the same
cellular model to determine whether they control the same
signalling pathways to promote tumorigenesis and develop
arguments in favour of an active MUC4-ErbB2 complex.
Our results clearly show that MUC4 and ErbB2 interact
physically in CAPAN-2 cells and that they activate different
signalling pathways, MUC4 activating the JNK pathway and
ErbB2 activating the p42/44 MAPK pathway. We also show that
they play roles in different properties of cancer cells with ErbB2
clearly affecting proliferation, cell cycle and tumour growth
whereas MUC4 shows a wider spectrum of activities ranging
from proliferation, cell cycle, tumour growth but also migration
and invasion. This adds to the complexity of MUC4 biological
activities in cancer since at least three major signalling pathways
are under its control in pancreatic cancer cells. The fact that
MUC4 affects a wider spectrum of biological activities may be
explained by the fact that it not only forms a complex with ErbB2
and participates in downstream cell signalling [13,28,30] but also
may have other partners at the membrane via its different modular
domains [4,29,31]. Indeed, MUC4 may alter migration/invasion
because of its huge glycosylated extracellular domain that has the
capacity to interact with numerous kinds of lectins, selectins, and
receptors. Alteration of mucin glycosylation is well-described in
cancer [4,29] and may modify MUC4 properties. Future
investigations will be useful to better understand MUC4 biology
related to its extracellular glycosylated domain as we found several
glycosyl/fucosyl/sialyl-transferases with decreased (ST3GAL6,
B3GNT5, B3GNT3, FUT8, FUT11) or increased (ST6GALNAC,
FUT1) expression in our microarray data (table S3). Galectins,
ErbB2 (green) by confocal microscopy showed co-localization of the two proteins (yellow). (E) Expression of MUC4 and ErbB2 in two representative
clones of MUC4-KD and ErbB2-KD cells and their respective controls (Mock and NT) by Western blotting.
doi:10.1371/journal.pone.0032232.g001
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properties [24,32,33], were found to be down-regulated in MUC4
deficient cells (galectin-1) (table S3). Recent work showed
interaction between MUC4 and galectin-3 [34], thus interaction
with the other galectins will have to be investigated in order to
show whether these interactions are specific or more general. This
illustrates the fact that the cellular context (environment) will have
profound impacts on MUC4 biological role. This is especially true
in pancreatic cancer where a huge stromal reaction surrounds
epithelial counterparts of the tumour [35,36,37,38]. Interestingly,
we found downregulation of several components (integrins a1/a5/
a6, epithelial-stromal interaction 1 (EPSTI1), fibronectin type III)
that may, together with altered MUC4 expression in cancer cells,
modify epithelial-stromal interactions. We also confirmed the
strong link between MUC4, ErbB2 and ErbB3 [13] that excludes
the two other members of the ErbB family (ErbB1 (EGF-R) and
ErbB4), since ErbB2 silencing reduced ErbB3 and MUC4
suppression led to a reduction in expression of both ErbB2 and
ErbB3.
Decreased proliferation in cells lacking MUC4 is most likely due
to the alteration of the JNK pathway since it is known that this
pathway promotes proliferation and decreased apoptosis in a
tumour context [39], two alterations that we found in MUC4-
deficient cells. It is also clearly associated with cell cycle arrest,
cyclin D1 repression as well as other members of cell cycle that we
found decreased (.2 fold decrease) in microarray analyses (cyclin
B1, cell division cycle 2 variant (CDC2), epithelial cell transform-
ing sequence 2 oncogene (ECT2), a protein elevated during the
G2-M phase of the cycle, cyclin G2) (table S3). Alteration of
proliferation in cells lacking ErbB2 is clearly associated with
Figure 2. Role of ErbB2 and MUC4 on cell proliferation, cell cycle apoptosis, migration and invasion properties of pancreatic cancer
cells. (A) Cell growth was assessed by cell counting at 24, 48, 72 and 96 h for CAPAN-2 MUC4-KD or ErbB2-KD and their respective controls (Mock
and NT). *=p,0.05 using student t-test. (B) Cell cycle distribution profiles of MUC4-KD, ErbB2-KD and their control clones (Mock and NT) by flow
cytometry following incubation with propidium iodure. The values are expressed as the mean of three independent experiments. *=p,0.05 using
Chi square test. ns=non significant. (C) Effect of MUC4 or ErbB2 silencing was analysed on cell cycle marker cyclin D1 and p27
kip1 by western blot. b-
actin was measured as the internal control. (D) Bands were quantified by densitometry. Histograms of the ratio (cyclin D1 or p27
kip1/b-actin) are
shown. (E) % of subG1 population of MUC4-KD, ErbB2-KD and controls (Mock and NT, respectively) was determined by flow cytometry following
incubation with propidium iodure (*=p,0.05). (F) Western blot were carried out for cleaved caspase 3, BclXL and Bax in MUC4-KD, ErbB2-KD and
their respective controls (Mock and NT). b-actin was evaluated as an internal control. (G) Migration properties of MUC4-KD, ErbB2-KD and control
clones (Mock and NT) were evaluated using Boyden chambers. Results are expressed as average migratory cell number per vision field (***=P,0.001,
ns=non significant). (H) % of invasion (invasive cells/migratory cells) was determined using Boyden chambers coated with MatrigelH.
doi:10.1371/journal.pone.0032232.g002
Figure 3. Impact of ErbB2 and MUC4 on MAPK/SAPK (p42/p44, JNK, p38) signalling pathways. (A) Western blot analyses were carried out
on cytosolic extract of MUC4-KD, ErbB2-KD and controls (Mock and NT respectively) for expression of both phosphorylated and constitutive forms of
p42/p44, JNK and p38 MAPK. b-actin was used as the internal control. Two representative clones are presented. (B) Bands were quantified by
densitometry. Histograms of the ratio (phosphorylated/constitutive form) for p42/p44, JNK and p38 MAPK kinases are shown.
doi:10.1371/journal.pone.0032232.g003
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pathways may be the activating protein-1 (AP-1), a transcription
factor known to regulate MUC4 [40] and cyclin D1 [41]
expression, the JNK pathway [42] and that is regulated by the
p42/44 MAPK pathway [41]. We hypothesize that lack of ErbB2
may induce a reduction of p42/p44 activation and therefore a
reduction of cyclin D1 and MUC4 expression via AP-1 (Figure 6).
AP-1, via alteration of the JNK pathway, could also be responsible
for the repression of the membrane-bound mucin MUC1 that was
observed in MUC4-KD cells, since the MUC1 promoter contains
several binding sites for AP-1 (Figure 6). Concerted regulation of
membrane-bound mucins has already been observed in vivo since
downregulation of Muc1 mRNA was detected in the Muc16
homozygous knock-out mouse [43]. This could reflect a more
general mechanism to counteract the absence of a membrane-
bound mucin in certain situations and allow normal function of
the cell [30,44].
Another important pathway in pancreatic tumour progression is
the TGF-b pathway that shows antagonistic effects on tumour cells
as it represses proliferation in the early stages and promotes
Figure 4. Effect of ErbB2 and MUC4 on tumour growth in vivo. (A) Subcutaneous xenograft of MUC4-KD (M4-2-1 and M4-2-10), ErbB2-KD (EV9
and EV18) and control (Mock-1 and NT5) cells were performed in six SCID mice. Relative tumour size was determined at day 22. (B) IHC analysis of
MUC4 and ErbB2 expression was analysed on extracted tumours. MUC4 is expressed at the membrane surface and within the cytoplasm in Mock cells
(insert). ErbB2 is expressed at the membrane surface in NT control cells (insert).
doi:10.1371/journal.pone.0032232.g004
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is a key regulator of MUC4 expression in pancreatic cancer cells
via the TGF-bRII/Smad3–4 pathway [20]. Accordingly, in
MUC4 deficient cells we found, in microarray analyses, inhibition
of Smad3 and TGF-bRII. We also found a strong induction of
TGF-b1 mRNA expression in cells lacking ErbB2 or MUC4.
From these results, we hypothesize that MUC4 inhibition induces
expression of TGF-b1 at the mRNA level to create a loop of
regulation (feedback) that would result in up-regulation of ErbB2
or MUC4 and promote tumour cell proliferation.
Despite the fact that it is thought that MUC4 may alter
migration/invasion/adherence properties of cancer cells via its
huge extracellular domain and modified steric hindrance [4,29],
adherence to two kinds of matrix was not modified in the absence
of MUC4 in our model. On the other hand, the observed
increased invasion in the absence of MUC4 was a bit surprising as
we did not find any significant variation of metalloproteinase
expression (MMP2, -7 or -9) (not shown) and decrease of collagen,
type VIII alpha 1 (COL8A1) expression, a component of the
stromal reaction in pancreatic cancer, was observed in microarray
analyses. Previous data indicated that increased FAK phosphor-
ylation and b-catenin levels in MUC4-transfected cells could
influence cell migration without directly altering cell adhesion
through its action on the ErbB2-ErbB3 complex [12,15]. Our
observation that MUC4 silencing leads to a decreased migration
but no alteration of cell adhesion is in accordance with these data.
The fact that FAK was not altered by MUC4 silencing in our
model suggests that this property may be mediated by yet another
pathway.
ErbB2 was not found to play major roles in cell migration/
invasion as cells lacking ErbB2 did not show any significant
alteration of migration/invasion despite the fact that we found a
significant increase of integrin-b6 and -b7 expression in the
transcriptome of ErbB2-KD cells. This may be explained by the
fact that these two integrins are involved in migration/invasion in
other cell types (keratynocytes) [46] or types of cancer (breast,
colon, stomach and ovary) [47,48,49] and that in pancreatic
cancer integrins b1/b4 seem more preponderant [50].
Finally, MUC4 activity on tumour cell properties is most likely
cell-specific (state of differentiation, tumour site origin: primary or
metastatic) as we did not find the same results with moderately
differentiated CAPAN-2 cells, which derive from a primary
tumour [51] when compared with previous studies conducted in
the poorly differentiated pancreatic cancer cell model HPAF-
CD18, which derives from peritoneal ascitic fluid [52].
In conclusion, we show that inhibition of ErbB2 and MUC4
expression did not impair the same signalling pathways (inhibition
of MUC4 expression affects the JNK pathway whereas that of
ErbB2 alters the MAPK pathway) and produced different effects
on pancreatic cancer cell biological properties, suggesting
independent activity of these two proteins (Figure 6). Our data
also suggests a role in pancreatic tumour growth for ErbB2, while
MUC4 is involved in both tumour growth and dissemination.
These data bring new information regarding molecular mecha-
nisms under the control of both MUC4 and ErbB2 that will have
to be taken into account for developing efficient targeting of both
proteins in order to slow down/stop pancreatic tumour develop-
ment.
Supporting Information
Figure S1 Expression of MUC1 membrane-bound mu-
cin and ErbB receptor family in the two representative
Figure 5. Validation of impact of ErbB2 and MUC4 on gene expression. Levels of expression of selected genes from microarray analysis were
studied by qRT-PCR in MUC4-KD clones (A) or ErbB2-KD clones (B). Expression levels were normalized to mRNA levels of GAPDH housekeeping gene
and shown as x-fold relative to the normalized expression of the respective target gene in Mock cells. Relative amounts of target genes were
calculated using the DDCt method. Values are means 6 SEM from four independent samples. *=p,0.05 using student t-test. **=p,0.01 using
student t-test.
doi:10.1371/journal.pone.0032232.g005
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blotting and their respective controls (Mock and NT).
(TIF)
Figure S2 Impact of ErbB2 and MUC4 on FAK and Akt
signalling pathways. Western blot were carried out for FAK,
phospho-Akt and Akt in MUC4-KD, ErbB2-KD and their
respective controls (Mock and NT). b-actin was used as the
internal control.
(TIF)
Figure S3 Venn diagram of regulated genes in MUC4-
KD vs Mock cells compared with ErbB2-KD vs NT cells.
(TIF)
Table S1 Primer sequences used for qRT-PCR.
(DOC)
Table S2 List of gene differentially-regulated (fold
change .2, p,0.05) in ErbB2-KD vs. NT control cells.
(XLS)
Table S3 List of gene differentially-regulated (fold
change .2, p,0.05) in MUC4-KD vs. Mock control cells.
(XLS)
Table S4 Gene Ontology Analysis of ErbB2-KD vs. NT
control cells.
(XLS)
Figure 6. Schematic representation of ErbB2 and MUC4 distinct roles on biological properties of CAPAN-2 pancreatic cancer cells.
doi:10.1371/journal.pone.0032232.g006
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Mock control cells.
(XLS)
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